The sensor safety endpoints were regularly assessed throughout the study; these included medical history, best-corrected visual acuity (using Early Treatment of Diabetic Retinopathy Study charts), visual field (static perimetry; protocol 24-2 SITA [Swedish Interactive Threshold Algorithm] Humphrey Field Analyzer [HFA; Carl Zeiss Meditec, Oberkochen, Germany]), IOP measurement (using Goldmann applanation tonometry [GAT], dynamic contour tonometry), slit-lamp examination, gonioscopy, ophthalmoscopy (retina, macula, and optic nerve with cup-to-disc ratio), Heidelberg retina tomography (Heidelberg Engineering, Heidelberg, Germany), endothelium evaluation (Confoscan; Nidek Technologies Srl, Padova, Italy), central corneal thickness (Pentacam; Oculus, Wetzlar, Germany), optical coherence tomography (OCT), ultrasound biomicroscopy (UBM), and assessment of adverse events. The following parameters were relevant for the primary endpoints: visual acuity; IOP; slit-lamp, fundus, and visual field examinations; gonioscopy; endothelium cell count; central corneal thickness; UBM; macular OCT scan; and adverse events.